FDA approves Mirum's oral drug for rare disease FOP
Mirum's new oral therapy for rare bone disease fibrodysplasia ossificans progressiva (FOP) looks set to challenge Regeneron's intravenous Pasatru.
Newsletters and Deep Dive digital magazine
Mirum's new oral therapy for rare bone disease fibrodysplasia ossificans progressiva (FOP) looks set to challenge Regeneron's intravenous Pasatru.
Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?
Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.
Editor's Picks
Newsletters and Deep Dive
digital magazine